B Group Inc. Takes Position in Palisade Bio, Inc. $PALI

B Group Inc. bought a new stake in Palisade Bio, Inc. (NASDAQ:PALI) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 4,500,000 shares of the company’s stock, valued at approximately $10,575,000. Palisade Bio comprises 7.8% of B Group Inc.’s investment portfolio, making the stock its 3rd biggest position.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Atom Investors LP acquired a new position in shares of Palisade Bio in the fourth quarter valued at approximately $33,000. Persistent Asset Partners Ltd bought a new stake in Palisade Bio in the 4th quarter valued at about $978,000. Squarepoint Ops LLC acquired a new position in shares of Palisade Bio during the 4th quarter worth approximately $757,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Palisade Bio during the 4th quarter worth approximately $254,000. Finally, Barclays PLC acquired a new position in shares of Palisade Bio during the 4th quarter worth approximately $35,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Analysts Set New Price Targets

PALI has been the topic of a number of analyst reports. HC Wainwright initiated coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They set a “buy” rating and a $7.00 target price on the stock. Weiss Ratings lowered shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Stifel Nicolaus initiated coverage on shares of Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price on the stock. Wolfe Research initiated coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.20.

Palisade Bio Trading Up 5.3%

NASDAQ PALI opened at $1.78 on Wednesday. The firm’s 50 day simple moving average is $1.98 and its 200 day simple moving average is $1.91. The firm has a market capitalization of $308.97 million, a price-to-earnings ratio of -1.76 and a beta of 1.52. Palisade Bio, Inc. has a 1 year low of $0.53 and a 1 year high of $2.86.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, equities research analysts forecast that Palisade Bio, Inc. will post -0.21 earnings per share for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.